Nubeqa – Talk Bio

Bayer’s Q3 Earnings Plummet 37%, CEO Urges Patience Amid Performance-Boosting Strategy

5 months ago talkbio0Tagged Avian crop, Bayer, Bill Anderson, CEO, decline, earnings, generics, Kerendia, Nubeqa, performance-boosting strategy

Bayer, Q3 earnings, decline, CEO Bill Anderson, performance-boosting strategy, pharmaceuticals, crop science, generics, Xarelto, Nubeqa, Kerendia.

Bayer Seeks to Broaden Nubeqa’s Use in Prostate Cancer with Chemotherapy-Free Treatment Option

7 months ago talkbio0Tagged Antiandrogen therapy, ARANOTE, Bayer, Chemotherapy-free, Clinical Trials, darolutamide, expansion, Labels (device), Malignant neoplasm of prostate, Metastatic to, mHSPC, Nubeqa

Nubeqa, Bayer, prostate cancer, chemotherapy-free, label expansion, ARANOTE trial, darolutamide, androgen deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC)

Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications

9 months ago talkbio0Tagged ARAMIS, ARASENS, Bayer, Clinical Trials, Corporation, darolutamide, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, non-metastatic castration-resistant prostate cancer, Nubeqa, Orion

NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation